Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021

Written by Customer Service on May 1, 2021. Posted in Public Companies.

AC – Inflammation was Mild and Decreasing over Time in Cohort 3 AC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflammation was Mild and Decreasing over Time in Cohort 3 Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3 Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3 Majority of Patients are Supplemental Injection Free after a Single IVT Injection of ADVM-022 in OPTIC Majority of Patients are Supplemental Injection Free after a Single IVT Injection of ADVM-022 in OPTIC Robust Aflibercept Expression Levels Observed for Both Doses in OPTIC Robust Aflibercept Expression Levels Observed for Both Doses in OPTIC; Within Modeled Therapeutic Range, Reaching...

Affinor Growers Files for Patent Protection in Eleven Additional Countries

Written by Customer Service on May 1, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, May 01, 2021 (GLOBE NEWSWIRE) — Affinor Growers Inc. (“Affinor” or the “Company”) (CSE: AFI; OTCQB: RSSFF) is pleased to announce it has filed for patent protection in eleven additional countries. United Arab Emirates Patent Application No. P6000245/2021 Saudi Arabia Patent Application No. 521421275 South Africa National Phase Entry of No. PCT/CA2019/051145 European Patent Office Patent Application No. 19852473.8 India Patent Application No. 202117011874 Republic of Korea Patent Application No. 10-2021-7008490 New Zealand Patent Application No. 774080 Australia Patent Application No. 2019324959 Aruba Patent Application No. OCT-01/180831 Colombia Patent Application No. NC2018/0009567 China Patent Application NO 201580020786.6 Affinor continues to protect its technology in the larger global markets...

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

Written by Customer Service on May 1, 2021. Posted in Public Companies.

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease BIIB122/DNL151 demonstrated a safety profile supporting continued development in patients with Parkinson’s disease Data support once daily oral dosing with BIIB122/DNL151 Denali and Biogen plan to advance BIIB122/DNL151 into late-stage development in patients with Parkinson’s disease by year-end 2021 SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor,...

HiPay: Availability of the Annual Report

Written by Customer Service on May 1, 2021. Posted in Public Companies.

HiPay: Availability of the Annual Report Paris, April 30, 2021: HiPay (ISIN code FR0012821916 – HIPAY), the fintech specialized in Omnichannel payment solutions, announces the availability of its annual report for the year ended December 31, 2020. This Annual Report includes the annual financial report, the report of the Board of Directors on corporate governance, the reports of the Statutory Auditors and information on their fees. The annual report can be consulted in the Investors section of the company’s website (https://hipay.com/en/investors). Next financial communication: June 3, 2021 – Vote results of the Annual General Meeting About HiPay HiPay is a global payment provider. By harnessing the power of payment data, we participate in our merchants’ growth by bringing them a 360° vision of their activities. More information...

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting

Written by Customer Service on May 1, 2021. Posted in Public Companies.

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5. Details of the Virtual Podium Presentation Title: The ONSET 2 Phase 3 Study of OC-01 Nasal Spray for the Treatment of Dry Eye Disease Authors: Michael Raizman, M.D.Session: Dry Eye Clinical Treatments session on May 1 at 3:15 EDT About OC-01 (varenicline) Nasal SprayOC-01...

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Written by Customer Service on May 1, 2021. Posted in Public Companies.

UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectively promotes apoptosis of diseased senescent cells of the retina, thereby restoring healthy vasculature and improving retinal function...

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting

Written by Customer Service on May 1, 2021. Posted in Public Companies.

Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 CAMBRIDGE, Mass., May 01, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held virtually May 1 – 7, 2021. The Company is presenting preclinical data on its Usher Syndrome 2A (USH2A) and retinitis pigmentosa 4 (RP4) programs. Editas Medicine’s presentations at ARVO will include preclinical data demonstrating: Gene edited USH2A exon 13 deletion restored USH2 protein complex expression and rescued deficits in photoreceptor morphology in human retinal organoids; and Clinically relevant levels of editing using a...

Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Written by Customer Service on May 1, 2021. Posted in Public Companies.

In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients1 More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME1 Beovu demonstrated an overall well-tolerated safety profile in KESTREL and KITE1 Phase III KESTREL and KITE trials are the first pivotal trials to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu may offer fewer injections from the start of treatment1 Novartis is committed to bringing Beovu 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021 Basel, May...

NIO Inc. Provides April 2021 Delivery Update

Written by Customer Service on May 1, 2021. Posted in Public Companies.

NIO delivered 7,102 vehicles in April 2021, increasing by 125.1% year-over-year Cumulative deliveries of the ES8, ES6 and EC6 as of April 30, 2021 reached 102,803 SHANGHAI, China, May 01, 2021 (GLOBE NEWSWIRE) — NIO Inc. (“NIO” or the “Company”) (NYSE: NIO), a pioneer and a leading manufacturer of premium smart electric vehicles in China, today provided its April 2021 delivery results. NIO delivered 7,102 vehicles in April 2021, representing a strong 125.1% year-over-year growth. The deliveries consisted of 1,523 ES8s, the Company’s six-seater and seven-seater flagship premium smart electric SUV, 3,163 ES6s, the Company’s five-seater high-performance premium smart electric SUV, and 2,416 EC6s, the Company’s five-seater premium smart electric coupe SUV. As of April 30, 2021, cumulative deliveries of the ES8, ES6 and EC6 reached...

Real People Investment Holdings Limited Preliminary Financial Update: Fourth quarter reduced impairment charges

Written by Customer Service on May 1, 2021. Posted in Public Companies.

Real People Investment Holdings Limited (RPIH) anticipates to release its 2021 annual results by no later than 30 June 2021. RPIH and its subsidiary companies (the Group) has maintained loan book valuation hair-cuts for Covid-19 on a forward looking basis to estimate and account for loan book performance risks. Loan book collections performance during the year to 31 March 2021 has been better than forecast during the peak of the Covid-19 pandemic. It is therefore likely that the impairment charges will be lower than previously expected and that the profit after tax will improve to a meaningful extent for the year to 31 March 2021 when compared to normalised operating results in prior years. The annual results for 2021 are not yet audited, and hence the numbers may be changed. * * * * * * * For further information, please contact: Neil...

Day: May 1, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice